Biotie Therapies’ Options Expand On Nalmefene And Tozadenant Progress

 
• By John Davis

Finland's only publicly listed biotech, Biotie Therapies, is reviewing its licensing and M&A options in niche CNS areas as product milestone payments and equity investments expand its cash runway.

The past six months have seen something of a turnaround in the fortunes of the Finland-based biotech Biotie Therapies Corp.

"We are now a company in transition, with cash, options and good news on our product pipeline, and we have...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography